Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome
Georgios N. Kalambokis, Epameinondas V. Tsianos – 29 July 2008
Reply:
Véronique Loustaud‐Ratti, Sophie Alain, Annick Rousseau, Pierre Marquet – 29 July 2008
Reply:
Robert J. Fontana – 29 July 2008
Reply:
Peter Ferenci, Ludwig Kramer – 29 July 2008
Reply:
Zachary D. Goodman, Hala R. Makhlouf, Lea Liu, William Balistreri, Regino P. Gonzalez‐Peralta, Barbara Haber, Maureen M. Jonas, Parvathi Mohan, Jean P. Molleston, Karen F. Murray, Michael R. Narkewicz, Philip Rosenthal, Lesley J. Smith, Kathleen B. Schwarz – 29 July 2008
Serum aminotransferase activity and mortality risk
Daniele Prati, Agostino Colli, Laura Porretti – 29 July 2008
Reply:
W. Ray Kim, Terry M. Therneau – 29 July 2008
Reply:
Joanne B. Krasnoff, Nathan M. Bass, Patricia L. Painter, Raphael B. Merriman – 29 July 2008
Weight‐adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short‐term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection
Martin Lagging, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Amar P. Dhillon, Åsa Alsiö, Kristoffer Hellstrand, Johan Westin, Peer Christensen, Peter Leutscher, Gunnar Norkrans – 29 July 2008
Reply:
Chia‐Ming Chu – 16 July 2008